Health Canada Responds To Probiotics Proliferation With Revised Regulation
This article was originally published in The Tan Sheet
Executive Summary
Canada’s evolving regulatory framework for probiotics may offer lessons for the U.S., though statutes constrain how much FDA can change.
You may also be interested in...
J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.
J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.
NDI Guidance Microorganism Stance Could Strain Probiotics Development
The growth of probiotics in supplements could slow to a crawl under FDA's new dietary ingredient notification draft guidance, industry stakeholders fear.